Patrick M Sweeney & Associates Inc. Has $2.91 Million Position in Pfizer Inc. (NYSE:PFE)

Patrick M Sweeney & Associates Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 46.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 114,818 shares of the biopharmaceutical company's stock after acquiring an additional 36,500 shares during the quarter. Pfizer makes up 2.2% of Patrick M Sweeney & Associates Inc.'s investment portfolio, making the stock its 8th largest holding. Patrick M Sweeney & Associates Inc.'s holdings in Pfizer were worth $2,909,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Tallon Kerry Patrick acquired a new stake in Pfizer in the fourth quarter valued at approximately $509,000. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Silver Oak Securities Incorporated increased its position in Pfizer by 13.7% during the fourth quarter. Silver Oak Securities Incorporated now owns 15,886 shares of the biopharmaceutical company's stock worth $420,000 after buying an additional 1,919 shares during the last quarter. Finally, Strategic Financial Concepts LLC bought a new position in Pfizer during the fourth quarter valued at about $2,281,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.13 during mid-day trading on Wednesday, hitting $24.43. The company had a trading volume of 25,108,330 shares, compared to its average volume of 40,976,849. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market cap of $138.87 billion, a P/E ratio of 17.32, a PEG ratio of 0.64 and a beta of 0.57. The business's 50-day simple moving average is $22.93 and its 200-day simple moving average is $24.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.82 EPS. As a group, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.04%. Pfizer's payout ratio is presently 124.64%.

Analyst Ratings Changes

A number of research analysts have recently commented on PFE shares. Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.